BrdU (Bromodeoxyuridine)

製品コードS7918 バッチS791808

印刷

化学情報

 Chemical Structure Synonyms 5-Bromo-2'-deoxyuridine, BUdR Storage
(From the date of receipt)
3 years -20°C(in the dark) powder
化学式

C9H11BrN2O5

分子量 307.1 CAS No. 59-14-3
Solubility (25°C)* 体外 DMSO 61 mg/mL (198.63 mM)
Ethanol (warmed with 50ºC water bath) 5 mg/mL (16.28 mM)
Water Insoluble
体内 (毎回新しく調製した物を用意してください)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液(一定の濃度)を調合する

生物活性

製品説明 BrdU (Bromodeoxyuridine) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.
in vitro

BrdU (Bromodeoxyuridine) induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion in RG2 rat glioma cells, and alters the cell cycle profile in H9 cells and BJ fibroblasts. [1]

It is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession. [2]

in vivo

In rat glioma RG2 tumor model, BrdU (Bromodeoxyuridine) (300 mg/kg, i.p. or 0.8 mg/ml, p.o.) significantly slows tumor progression. [1]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 RG2 rat glioma cells
濃度 ~ 50 µM
反応時間 24 hours
実験の流れ

Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 µM BrdU (Bromodeoxyuridine) for 24 hours, and cumulative growth curves were obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment with this compound.

動物実験 動物モデル Rats bearing RG2 tumors
投薬量 300 mg/kg (i.p.); 0.8 mg/ml (p.o.)
投与方法 i.p. or p.o.

参考

  • https://pubmed.ncbi.nlm.nih.gov/18680882/
  • https://pubmed.ncbi.nlm.nih.gov/18770853/

カスタマーフィードバック

Data from [Data independently produced by , , PLoS One, 2016, 11(11):e0166386.]

Data from [Data independently produced by , , PLoS One, 2016, 11(11):e0166386]

Data from [Data independently produced by , , Int J Ophthalmol, 2017, 10(4):507-514]

Selleckの高級品が、幾つかの出版された研究調査結果(以下を含む)で使われた:

A Neutrophil Storage Pool in the Fetal Liver is the Principal Source of the Postnatal Neutrophil Surge [ FASEB J, 2025, 39(15):e70921] PubMed: 40767082
Lipotoxicity-induced upregulation of FIS1 exacerbates mitochondrial fragmentation and promotes NLRP3-dependent pyroptosis in diabetic cardiomyopathy [ Free Radic Biol Med, 2024, 228:183-196] PubMed: 39734056
Hippocampal mitophagy contributes to spatial memory via maintaining neurogenesis during the development of mice [ CNS Neurosci Ther, 2024, 30(6):e14800] PubMed: 38887162
Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII [ Heliyon, 2024, 10(3):e24779] PubMed: 38314260
Survivin inhibition attenuates EGF-induced epithelial mesenchymal transformation of human RPE cells via the EGFR/MAPK pathway [ PLoS One, 2024, 19(8):e0309539] PubMed: 39213375
Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway [ Int J Ophthalmol, 2024, 17(6):1018-1027] PubMed: 38895677
miR-432-5p Inhibits the Ferroptosis in Cardiomyocytes Induced by Hypoxia/Reoxygenation via Activating Nrf2/SLC7A11 Axis by Degrading Keap1 [ Anal Cell Pathol -Amst), 2023, 2023:1293200] PubMed: 37822721
CDCA8, targeted by MYBL2, promotes malignant progression and olaparib insensitivity in ovarian cancer [ Am J Cancer Res, 2021, 11(2):389-415] PubMed: 33575078
Activation of 6-8-week-old new mature adult-born dentate granule cells contributes to anxiety-like behavior [ Neurobiol Stress, 2021, 15:100358] PubMed: 34195305
YM155 inhibits retinal pigment epithelium cell survival through EGFR/MAPK signaling pathway [ Int J Ophthalmol, 2021, 14(4):489-496] PubMed: 33875937

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。